AbbVie Inc v. Micro Labs Ltd

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: AbbVie Inc. (Delaware) and Allergan Pharmaceuticals International Limited (Ireland)
  • Defendant: Micro Labs Limited (India) and Micro Labs USA, Inc. (New Jersey)
  • Plaintiff's Counsel: McCarter & English, LLP
• Case Identification: 3:26-cv-10379, D.N.J., 08/14/2026
• Venue Allegations: Venue is asserted as proper in the District of New Jersey because Defendant Micro Labs USA, Inc. maintains its principal place of business in the district, and Defendant Micro Labs Limited, an Indian corporation, may be sued in any U.S. judicial district.
• Core Dispute: Plaintiffs allege that Defendant's filing of an Abbreviated New Drug Application (ANDA) to market a generic version of the migraine prevention drug QULIPTA® (atogepant) constitutes an act of infringement of patents covering specific dosing regimens.
• Technical Context: The patents-in-suit relate to methods for safely and effectively administering the CGRP receptor antagonist atogepant to specific migraine patient subpopulations, such as those with certain medical conditions or those taking other specific medications that may cause drug-drug interactions.
• Key Procedural History: Plaintiffs previously filed a separate lawsuit against Micro Labs on January 15, 2026 (the "First Suit") concerning other patents related to atogepant. The current action was initiated in response to a subsequent "Third Notice Letter" from Micro Labs, dated January 5, 2026, which included a Paragraph IV certification against one of the patents-in-suit.

Case Timeline

Date	Event
2021-09-27	Priority Date for '897 and '341 Patents
2021-09-28	FDA Approval of QULIPTA® (NDA No. 215206)
2025-12-04	Micro Labs sends "First Notice Letter" regarding other patents
2026-01-05	Micro Labs sends "Second" and "Third" Notice Letters
2026-01-15	Plaintiffs file "First Suit" against Micro Labs
2026-05-12	U.S. Patent No. 12,622,897 Issues
2026-06-23	U.S. Patent No. 12,661,341 Issues
2026-08-14	Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 12,622,897 ("the '897 Patent") - Methods of Treating Migraine (Issued May 12, 2026)

The Invention Explained

• Problem Addressed: The patent addresses the need for specific, targeted dosing regimens for oral Calcitonin Gene-Related Peptide (CGRP) treatments to prevent migraines, particularly in patient populations where drug-drug interactions could affect safety and efficacy '897 Patent, col. 1:36-44
• The Patented Solution: The patent discloses methods for the preventive treatment of migraine in patients who are concurrently taking other specific drugs, known as OATP inhibitors, which can significantly alter the concentration of atogepant in the body '897 Patent, col. 4:1-12 The claimed solution is to administer a specific, lower dose of atogepant (10 mg or 30 mg once daily) to these patients to account for the interaction and maintain a safe and effective therapeutic window '897 Patent, col. 6:45-54
• Technical Importance: Because atogepant is a substrate of transport proteins like OATP1B1, co-administration with inhibitors of these transporters can significantly increase atogepant exposure, creating a need for dose adjustments to avoid potential adverse effects '897 Patent, col. 4:5-12

Key Claims at a Glance

• The complaint alleges infringement of one or more claims of the patent without specifying them Compl. ¶69 The independent claims are Claims 1 and 6.
• Independent Claim 1 Elements:
  • A method for the preventive treatment of migraine
  • in a patient undergoing concurrent treatment with an OATP inhibitor,
  • the method comprising orally administering a therapeutically effective dose of 10 mg atogepant once daily
  • to the patient, wherein the patient's migraines are safely and effectively treated.
• Independent Claim 6 is structurally similar but recites a dose of 30 mg atogepant once daily.

U.S. Patent No. 12,661,341 ("the '341 Patent") - Methods of Treating Migraine (Issued June 23, 2026)

The Invention Explained

• Problem Addressed: The patent identifies a need for defined, safe, and effective dosing regimens for atogepant in patients with pre-existing medical conditions, such as hepatic (liver) impairment, which could alter how the drug is metabolized '341 Patent, col. 1:30-38
• The Patented Solution: The patent provides a method for preventively treating migraine in patients who have mild or moderate hepatic impairment. It discloses that while atogepant exposure is slightly increased in these patients, the change is not clinically significant, and therefore the standard doses of 10 mg, 30 mg, or 60 mg once daily can be safely administered without adjustment '341 Patent, col. 9:1-16 The invention is the validated finding that no dose adjustment is necessary in this specific patient population.
• Technical Importance: Establishing that a standard dose of a drug is safe in a population with impaired liver function is a critical step for regulatory approval and provides essential guidance for prescribing physicians, avoiding the need for complex dose-finding in clinical practice '341 Patent, col. 9:48-59

Key Claims at a Glance

• The complaint alleges infringement of one or more claims without specifying them Compl. ¶98 The sole independent claim is Claim 1.
• Independent Claim 1 Elements:
  • A method for the preventive treatment of migraine
  • in a patient having mild or moderate hepatic impairment,
  • the method comprising orally administering a dose selected from the group consisting of 10 mg, 30 mg, and 60 mg atogepant once daily to the patient.
• The complaint does not explicitly reserve the right to assert dependent claims, but this is standard practice.

III. The Accused Instrumentality

Product Identification

The accused products are Micro Labs' generic atogepant oral tablets in 10 mg, 30 mg, and 60 mg dosage forms, for which Micro Labs submitted ANDA No. 220772 to the FDA Compl. ¶50

Functionality and Market Context

• The complaint alleges that Micro Labs' ANDA seeks approval for a generic product that is bioequivalent to Plaintiffs' QULIPTA® Tablets Compl. ¶60 The infringement allegation is predicated on the assertion that the proposed labeling for Micro Labs' generic product will recommend the same conditions of use as QULIPTA®, including its use for the preventive treatment of migraine in adults Compl. ¶¶37, 61
• This includes, according to the complaint, dosing instructions for specific patient populations, such as those with mild or moderate hepatic impairment and those concomitantly using OATP inhibitors Compl. ¶39 The complaint notes that QULIPTA® is the only oral CGRP receptor antagonist with a recommended dosage modification for patients also using OATP inhibitors, suggesting this is a key commercial feature Compl. ¶40

No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

The complaint alleges infringement under 35 U.S.C. § 271(e)(2)(A), which makes the submission of an ANDA for a generic drug an act of infringement if the purpose is to market the drug before patent expiration Compl. ¶69; Compl. ¶98 The theory of infringement is that Micro Labs' proposed product label will instruct medical professionals and patients to administer the generic drug in a manner that directly infringes the patented methods, constituting induced infringement under 35 U.S.C. § 271(b) upon commercial launch Compl. ¶71; Compl. ¶100

'897 Patent Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A method for the preventive treatment of migraine...	The complaint alleges Micro Labs' proposed product label will have the same indication as QULIPTA®, which is for the preventive treatment of migraine in adults.	¶37; ¶61	col. 2:46-51
...in a patient undergoing concurrent treatment with an OATP inhibitor,	The complaint alleges the QULIPTA® label, which Micro Labs' proposed label will allegedly mirror, contains a dosage modification for patients concomitantly using OATP inhibitors.	¶39; ¶40	col. 6:45-54
...the method comprising orally administering a therapeutically effective dose of 10 mg atogepant once daily...	The complaint states the recommended dose for QULIPTA® for patients concomitantly using OATP inhibitors is 10 mg or 30 mg once daily, which Micro Labs' generic product will allegedly adopt.	¶39	col. 6:49-51

'341 Patent Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A method for the preventive treatment of migraine...	The complaint alleges Micro Labs' proposed product label will have the same indication as QULIPTA®, which is for the preventive treatment of migraine.	¶37; ¶61	col. 2:46-51
...in a patient having mild or moderate hepatic impairment,	The complaint alleges the QULIPTA® label, which Micro Labs' proposed label will allegedly mirror, includes a safe and effective dosing regimen for patients with mild or moderate hepatic impairment.	¶39	col. 9:1-8
...the method comprising orally administering a dose selected from the group consisting of 10 mg, 30 mg, and 60 mg atogepant once daily to the patient.	The complaint states that these doses are recommended for patients with mild or moderate hepatic impairment on the QULIPTA® label, which the generic will allegedly copy.	¶39	col. 38:62-67

Identified Points of Contention

• Scope Questions: The central dispute will likely concern the final language of the FDA-approved label for Micro Labs' generic product. A key question for the court will be whether Micro Labs can, and does, "carve out" the patented methods of use from its label. The complaint suggests a carve-out for the OATP inhibitor interaction may be difficult, as it alleges QULIPTA® is unique in this regard, raising the question of whether a generic without this guidance would be deemed less safe or effective (Compl. ¶40; Compl. ¶61).
• Technical Questions: As this is an ANDA case based on paperwork, the dispute is not about how Micro Labs' product physically works but about what its label will instruct users to do. The key evidentiary question will be whether the content of Micro Labs' ANDA filing, specifically its proposed label, directs, encourages, or recommends the performance of the steps recited in the asserted claims.

V. Key Claim Terms for Construction

For the '897 Patent

• The Term: "concurrent treatment"
• Context and Importance: This term defines the circumstance under which the specific 10 mg or 30 mg dosage is required. The infringement analysis depends on whether a patient receiving Micro Labs' generic product would be considered to be undergoing "concurrent treatment" with an OATP inhibitor as instructed by the proposed label. Practitioners may focus on this term's temporal scope.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The specification uses the term "concomitantly" and describes co-administration without imposing a strict temporal limitation, which may support an interpretation that covers any overlapping period of prescriptions for atogepant and an OATP inhibitor '897 Patent, col. 4:13-19
  • Evidence for a Narrower Interpretation: A party could argue that the term implies administration within a timeframe that causes a clinically significant drug-drug interaction, potentially limiting its scope. The patent's examples focus on specific study designs that could be used to argue for a more constrained definition '897 Patent, Example 10

For the '341 Patent

• The Term: "mild or moderate hepatic impairment"
• Context and Importance: This term defines the patient population for the method claimed in the '341 Patent. Proving infringement will require showing that the accused generic product is labeled for use in this specific population.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The plain meaning of the term encompasses a range of liver conditions.
  • Evidence for a Narrower Interpretation: The patent specification provides a very specific definition, explicitly tying the terms to the Child-Pugh classification system: "mild hepatic impairment refers to Child-Pugh Class A; moderate hepatic impairment refers to Child-Pugh Class B" '341 Patent, col. 9:6-8 This express definition will likely control the term's construction, making significant disputes over its meaning less probable.

VI. Other Allegations

Indirect Infringement

The core of the plaintiffs' case rests on indirect infringement, specifically induced infringement under 35 U.S.C. § 271(b). The complaint alleges that Micro Labs is aware of the patents-in-suit and that by seeking approval for a generic product with labeling that mirrors QULIPTA®'s patented uses, it intends for healthcare professionals and patients to directly infringe the patents Compl. ¶¶71-73 Compl. ¶¶100-102 Knowledge is alleged based on Micro Labs' Paragraph IV certification for the '897 patent and the filing of the complaint itself for the '341 patent Compl. ¶54 Compl. ¶95

Willful Infringement

The complaint does not contain an explicit count for willful infringement. However, it does request a declaration that the case is "exceptional" and an award of attorney fees pursuant to 35 U.S.C. § 285, which is the statutory remedy often associated with findings of willfulness or other litigation misconduct Compl., Prayer G

VII. Analyst's Conclusion: Key Questions for the Case

• A core issue will be one of regulatory labeling and inducement: Can Micro Labs obtain FDA approval for a generic atogepant label that successfully "carves out" the patented dosing regimens for patients with hepatic impairment or those taking OATP inhibitors? If not, will the act of marketing a product with a label that instructs those uses be found to induce infringement?
• A related question is one of commercial viability versus infringement risk: Given the complaint's allegation that QULIPTA® is the only oral CGRP antagonist with a specific dose modification for OATP inhibitor use, a key strategic question is whether Micro Labs can market a viable generic competitor if it is forced to omit this safety information from its label, or if it will proceed with a potentially infringing label and challenge the patents' validity or infringement allegations in court.
• Finally, a procedural question for the '341 patent will be one of notice and ripeness: The complaint alleges that Plaintiffs have not yet received a Paragraph IV certification for the '341 patent but that infringement is demonstrated by Micro Labs' ANDA filing and regulatory requirements. The court may need to address whether the infringement and declaratory judgment claims for this patent are ripe for adjudication in the absence of a formal Paragraph IV notice letter from the defendant.